Oleate-mediated activation of phospholipase D and mammalian target of rapamycin (mTOR) regulates proliferation and rapamycin sensitivity of hepatocarcinoma cells.
OBJECTIVE
A high-fat diet and obesity are associated with increased risk of liver cancer. Because increased delivery of NEFA to the liver occurs in these conditions, we investigated the involvement of the unsaturated fatty acid oleate in hepatocarcinoma cell proliferation using human-derived hepatocarcinoma cell lines as model systems.


METHODS
Western blotting, FACS analysis and [(3)H]thymidine incorporation were used to study the signalling pathways and the proliferation of cells cultured for up to 72 h with or without a concentration of oleate considered to be relevant to human pathophysiology (50 μmol/l) or a concentration considered elevated (1 mmol/l).


RESULTS
In HepG2 cells, proliferation was increased in the presence of 50 μmol/l oleate, but was decreased at 1 mmol/l. This differential effect was correlated with the activation of the mammalian target of rapamycin complex 1 (mTORC1) and with increased translation of cell cycle regulators. Oleate-mediated mTORC1 activation required phospholipase D activation, which produces phosphatidic acid and is known to render mTORC1 rapamycin resistant. Remarkably, rapamycin resistance was found to affect specifically the mTORC1/eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) branch of the mTORC1 pathway in the presence of 50 μmol/l oleate. Furthermore, inhibition of phosphatidic acid production abolished oleate-induced increases in mTORC1 activity and cyclin A production. Importantly, the same differential effects of oleate on mTORC1 activation, cell cycle regulators and rapamycin resistance were found in SK-Hep1 cells.


CONCLUSIONS
Oleate stimulates mTORC1 activation and rapamycin resistance. We propose that rapamycin-derived mTOR inhibitors are likely to be of limited therapeutic use to restrain hepatic tumour growth, particularly in the context of associated obesity.
Faculté de Médecine, Institut de Génétique et Signalisation Moléculaire, Université de Nice-Sophia Antipolis, Nice, France. arous@unice.fr
C
C
Arous
M
M
Naïmi
E
E
Van Obberghen
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D015153:Blotting, Western; D018797:Cell Cycle Proteins; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D019925:Cyclin A / Q000378:metabolism; D005434:Flow Cytometry; D056945:Hep G2 Cells; D006801:Humans; D000076222:Mechanistic Target of Rapamycin Complex 1; D046912:Multiprotein Complexes; D019301:Oleic Acid / Q000494:pharmacology*; D010739:Phospholipase D / Q000235:genetics / Q000378:metabolism*; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases; D014280:Triglycerides / Q000378:metabolism
D048868:Adaptor Proteins, Signal Transducing; D018797:Cell Cycle Proteins; D019925:Cyclin A; C087000:EIF4EBP1 protein, human; D046912:Multiprotein Complexes; D010750:Phosphoproteins; D011506:Proteins; D014280:Triglycerides; D019301:Oleic Acid; D000076222:Mechanistic Target of Rapamycin Complex 1; D058570:TOR Serine-Threonine Kinases; D010739:Phospholipase D; D020123:Sirolimus
Hepatology. 2003 Mar;37(3):534-43
12601350
Mol Cell Biol. 2009 Feb;29(3):640-9
19047368
J Hepatol. 2009 Jun;50(6):1132-41
19398230
J Clin Invest. 2008 Sep;118(9):3065-74
18725988
Cell Metab. 2008 Jan;7(1):11-20
18177721
Science. 2001 Nov 30;294(5548):1942-5
11729323
Mol Cell. 2000 Jul;6(1):77-86
10949029
Curr Opin Cell Biol. 1998 Apr;10(2):268-75
9561852
J Biol Chem. 2001 Nov 2;276(44):40968-76
11533045
Cell Metab. 2009 Apr;9(4):311-26
19356713
Oncogene. 2010 May 6;29(18):2746-52
20190810
Biochem Biophys Res Commun. 2007 Oct 12;362(1):206-211
17698034
J Biol Chem. 2001 Apr 6;276(14):10943-51
11278364
Mol Cancer Ther. 2010 Jun;9(6):1740-54
20530718
Annu Rev Pathol. 2010;5:145-71
20078219
Mol Cell Biol. 2004 Jan;24(1):200-16
14673156
Oncogene. 2010 Sep 9;29(36):4989-5005
20639898
Cancer Lett. 2010 Dec 18;299(1):72-9
20805015
J Hepatol. 2009 Oct;51(4):725-33
19665249
Biochim Biophys Acta. 2009 Sep;1791(9):949-55
19264150
Science. 2006 Sep 15;313(5793):1581-2
16973864
Nat Rev Cancer. 2004 Aug;4(8):579-91
15286738
Curr Biol. 2009 Dec 1;19(22):R1046-52
19948145
Hepatology. 2004 Dec;40(6):1322-32
15565660
Int J Oncol. 2004 Dec;25(6):1839-47
15547725
J Biol Chem. 2006 Apr 28;281(17):12093-101
16505490
FEBS Lett. 1991 Oct 21;291(2):229-32
1657643
FEBS Lett. 1999 Jul 2;454(1-2):42-6
10413092
FASEB J. 2007 Apr;21(4):1075-87
17242159
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3441-6
20133650
Histochemistry. 1992 Jul;97(6):493-7
1385366
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17414-9
18955708
Cell. 2010 Jan 22;140(2):197-208
20141834
Semin Liver Dis. 1999;19(3):243-52
10518304
Gastroenterology. 2004 Nov;127(5 Suppl 1):S97-103
15508109
Mol Endocrinol. 2003 Dec;17(12):2448-60
14500759
Mol Cell Biol. 2009 Mar;29(6):1411-20
19114562
J Biol Chem. 2009 Mar 20;284(12):8023-32
19150980
Cell. 2006 Feb 10;124(3):471-84
16469695